Tuesday, March 6, 2012

CytomX names Hoyoung Huh as chairman

Antibody development company CytomX Therapeutics Inc. named biotech veteran Dr. Hoyoung Huh as chairman.
The privately held company, which moved to South San Francisco after lining up $30 million in financing in 2010, is developing monoclonal antibodies that can target specific tissues in cancer, inflammatory disease and autoimmune conditions.

No comments:

Post a Comment